Login to Your Account



Celgene, Amylin Fourth Quarter Earnings Impress

By Catherine Shaffer


Friday, January 28, 2011
Celgene Corp.'s fourth quarter non-GAAP earnings of $347.6 million, and its 2010 net non-GAAP earnings of $1.315 billion allowed it to end the year on a positive note. A 45 percent increase in Revlimid sales, at $2.47 billion, led the surge in earnings, with Vidaza also on the rise, and Thalomid and Abraxane contributing solidly. Celgene guidance calls for further growth in 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription